Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Ayala Pharmaceuticals, Inc is a biotechnology business based in the US. Ayala Pharmaceuticals shares (AYLA) are listed on the NASDAQ and all prices are listed in US Dollars. Ayala Pharmaceuticals employs 31 staff and has a trailing 12-month revenue of around USD$3.1 million.
|Latest market close||USD$13.2|
|52-week range||USD$8.62 - USD$16.5|
|50-day moving average||USD$10.8721|
|200-day moving average||USD$11.6628|
|Wall St. target price||USD$21.6|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||6.71%|
|1 month (2020-12-18)||14.29%|
|3 months (2020-10-19)||13.2|
|6 months (2020-07-17)||5.60%|
|1 year (2020-01-15)||N/A|
|2 years (2019-01-15)||N/A|
|3 years (2018-01-15)||N/A|
|5 years (2016-01-15)||N/A|
|Revenue TTM||USD$3.1 million|
|Gross profit TTM||USD$1 million|
|Return on assets TTM||-46.93%|
|Return on equity TTM||0%|
|Market capitalisation||USD$150.1 million|
TTM: trailing 12 months
There are currently 15,707 Ayala Pharmaceuticals shares held short by investors – that's known as Ayala Pharmaceuticals's "short interest". This figure is 23.9% up from 12,678 last month.
There are a few different ways that this level of interest in shorting Ayala Pharmaceuticals shares can be evaluated.
Ayala Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ayala Pharmaceuticals shares currently shorted divided by the average quantity of Ayala Pharmaceuticals shares traded daily (recently around 16027.551020408). Ayala Pharmaceuticals's SIR currently stands at 0.98. In other words for every 100,000 Ayala Pharmaceuticals shares traded daily on the market, roughly 980 shares are currently held short.
However Ayala Pharmaceuticals's short interest can also be evaluated against the total number of Ayala Pharmaceuticals shares, or, against the total number of tradable Ayala Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ayala Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Ayala Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0025% of the tradable shares (for every 100,000 tradable Ayala Pharmaceuticals shares, roughly 3 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ayala Pharmaceuticals.
Find out more about how you can short Ayala Pharmaceuticals stock.
We're not expecting Ayala Pharmaceuticals to pay a dividend over the next 12 months.
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.